Maraviroc

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV/AIDS

Conditions

HIV/AIDS

Trial Timeline

May 1, 2008 → Mar 1, 2010

NCT ID

NCT00775294

About Maraviroc

Maraviroc is a phase 1 stage product being developed by Pfizer for HIV/AIDS. The current trial status is completed. This product is registered under clinical trial identifier NCT00775294. Target conditions include HIV/AIDS.

What happened to similar drugs?

3 of 5 similar drugs in HIV/AIDS were approved

Approved (3) Terminated (1) Active (2)

✅TruvadaGilead SciencesApproved

✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved

✅Emtricitabine and TenofovirGilead SciencesApproved

🔄Biktarvy + SymtuzaGilead SciencesPhase 3

🔄TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02934022	Pre-clinical	Completed	Jun 1, 2012	Dec 1, 2014	HIV Infection
NCT01384682	Approved	Completed	Aug 1, 2011	Dec 1, 2015	HIV
NCT01276236	Phase 2	Completed	Mar 9, 2011	Apr 30, 2015	Kaposi's Sarcoma
NCT01133210	Phase 1	Completed	Jan 1, 2011	Nov 1, 2012	Hypertriglyceridemia
NCT00944541	Phase 2	Completed	Sep 1, 2009	Jan 1, 2011	HIV Infection
NCT00982878	Phase 1	Completed	Sep 1, 2009	Feb 1, 2011	HIV Infections
NCT00801515	Pre-clinical	Completed	Aug 1, 2009	Jul 1, 2011	HIV
NCT00850395	Pre-clinical	Completed	Jul 1, 2009	Oct 1, 2011	HIV-1
NCT00791700	Phase 2	UNKNOWN	Apr 22, 2009	Jun 30, 2023	Human Immunodeficiency Virus
NCT00925756	Approved	Completed	Oct 20, 2008	Apr 11, 2014	HIV Infections
NCT00719823	Phase 3	Withdrawn	Aug 1, 2008	May 1, 2010	Human Immunodeficiency Virus Type 1
NCT00775294	Phase 1	Completed	May 1, 2008	Mar 1, 2010	HIV/AIDS
NCT00795444	Phase 2	Completed	Mar 1, 2008	Jan 1, 2015	HIV-1
NCT00703586	Phase 1	Completed	Sep 1, 2007	May 1, 2011	HIV Infections
NCT00478231	Phase 3	Completed	Jul 1, 2007	Sep 1, 2010	Acquired Immunodeficiency Syndrome
NCT00496782	Phase 1	Terminated	Jul 1, 2007	Oct 1, 2008	HIV Infections

Competing Products

11 competing products in HIV/AIDS

See all competitors

Product	Company	Stage	Hype Score
Metformin	Merck	Phase 2/3	34
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC	Gilead Sciences	Pre-clinical	18
Switch to E/C/FTC/TAF daily	Gilead Sciences	Phase 1/2	32
Biktarvy + Symtuza	Gilead Sciences	Phase 3	40
Truvada	Gilead Sciences	Approved	43
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)	Gilead Sciences	Approved	35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet	Gilead Sciences	Phase 2	35
Emtricitabine and Tenofovir	Gilead Sciences	Approved	39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets	Gilead Sciences	Phase 3	47
Efavirenz	Bristol Myers Squibb	Pre-clinical	26
Moxifloxacin + Placebo + Efavirenz	Bristol Myers Squibb	Phase 1	29